PT2678679T - Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos - Google Patents
Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolosInfo
- Publication number
- PT2678679T PT2678679T PT127048262T PT12704826T PT2678679T PT 2678679 T PT2678679 T PT 2678679T PT 127048262 T PT127048262 T PT 127048262T PT 12704826 T PT12704826 T PT 12704826T PT 2678679 T PT2678679 T PT 2678679T
- Authority
- PT
- Portugal
- Prior art keywords
- furazanobenzimidazoles
- biomarker
- drug response
- acetylated tubulin
- tubulin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11155774 | 2011-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2678679T true PT2678679T (pt) | 2017-04-07 |
Family
ID=44065555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127048262T PT2678679T (pt) | 2011-02-24 | 2012-02-21 | Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9476889B2 (pt) |
| EP (1) | EP2678679B1 (pt) |
| JP (1) | JP6295081B2 (pt) |
| CN (1) | CN103392130B (pt) |
| AU (1) | AU2012219611C1 (pt) |
| CA (1) | CA2824497A1 (pt) |
| DK (1) | DK2678679T3 (pt) |
| ES (1) | ES2621413T3 (pt) |
| HU (1) | HUE032187T2 (pt) |
| PL (1) | PL2678679T3 (pt) |
| PT (1) | PT2678679T (pt) |
| WO (1) | WO2012113802A1 (pt) |
| ZA (1) | ZA201306086B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10006078B2 (en) * | 2011-03-29 | 2018-06-26 | Basilea Pharmaceutica Ag | Use of phospho-Akt as a biomarker of drug response |
| US10392920B2 (en) * | 2013-12-05 | 2019-08-27 | Schlumberger Technology Corporation | Method and system of quantitative cement evaluation using logging while drilling |
| US10578455B2 (en) * | 2014-03-06 | 2020-03-03 | Mitsubishi Heavy Industries, Ltd. | Device for providing electric-moving-body information and method for providing electric-moving-body information |
| EP3365680A1 (en) | 2015-10-22 | 2018-08-29 | Basilea Pharmaceutica International AG | Use of eb1 as a biomarker of drug response |
| MX388196B (es) | 2017-04-26 | 2025-03-19 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| WO2018210868A1 (en) | 2017-05-16 | 2018-11-22 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| WO2019097073A1 (en) * | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| CN109053584B (zh) * | 2018-09-12 | 2022-03-18 | 南京大学 | 一类1,2-二芳基苯并咪唑衍生物的制备及其应用 |
| EP3853224A1 (en) * | 2018-09-20 | 2021-07-28 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| KR102503593B1 (ko) * | 2020-03-11 | 2023-02-24 | 연세대학교 산학협력단 | 항암제 내성 진단 또는 치료용 조성물 |
| WO2021186855A1 (ja) * | 2020-03-16 | 2021-09-23 | 株式会社マンダム | T細胞性リンパ腫の指標の検出方法、及びその利用 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
| EP4551943A1 (en) * | 2022-07-06 | 2025-05-14 | I3S - Instituto de Investigação e Inovação em Saúde, Associação | Tubulin acetylation and its associated post-translational modifications as biomarkers of response to treatment with taxol, taxanes and other microtubule stabilizing anti-cancer agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030095953A1 (en) * | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| AU2002361022A1 (en) * | 2001-12-07 | 2003-06-17 | Novartis Ag | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
| DK1636215T3 (da) | 2003-05-23 | 2008-06-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoler |
| US8999289B2 (en) | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| CA2679393A1 (en) * | 2007-03-05 | 2008-09-12 | Newsouth Innovations Pty Limited | Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents |
| CN101861151B (zh) * | 2007-09-14 | 2014-08-13 | 梅特希尔基因公司 | 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗 |
| NZ597376A (en) * | 2009-07-27 | 2014-01-31 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
-
2012
- 2012-02-21 US US13/983,887 patent/US9476889B2/en not_active Expired - Fee Related
- 2012-02-21 HU HUE12704826A patent/HUE032187T2/en unknown
- 2012-02-21 PT PT127048262T patent/PT2678679T/pt unknown
- 2012-02-21 CA CA2824497A patent/CA2824497A1/en not_active Abandoned
- 2012-02-21 WO PCT/EP2012/052954 patent/WO2012113802A1/en not_active Ceased
- 2012-02-21 ES ES12704826.2T patent/ES2621413T3/es active Active
- 2012-02-21 EP EP12704826.2A patent/EP2678679B1/en active Active
- 2012-02-21 AU AU2012219611A patent/AU2012219611C1/en not_active Ceased
- 2012-02-21 CN CN201280010196.1A patent/CN103392130B/zh not_active Expired - Fee Related
- 2012-02-21 PL PL12704826T patent/PL2678679T3/pl unknown
- 2012-02-21 DK DK12704826.2T patent/DK2678679T3/en active
- 2012-02-21 JP JP2013554872A patent/JP6295081B2/ja not_active Expired - Fee Related
-
2013
- 2013-08-13 ZA ZA2013/06086A patent/ZA201306086B/en unknown
-
2016
- 2016-10-14 US US15/294,157 patent/US10067120B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK2678679T3 (en) | 2017-04-24 |
| JP2014511486A (ja) | 2014-05-15 |
| ZA201306086B (en) | 2014-04-30 |
| EP2678679A1 (en) | 2014-01-01 |
| PL2678679T3 (pl) | 2017-07-31 |
| CN103392130B (zh) | 2015-11-25 |
| HK1191096A1 (zh) | 2014-07-18 |
| US20170122934A1 (en) | 2017-05-04 |
| AU2012219611C1 (en) | 2016-07-21 |
| AU2012219611B2 (en) | 2016-03-03 |
| US9476889B2 (en) | 2016-10-25 |
| EP2678679B1 (en) | 2017-02-08 |
| AU2012219611A1 (en) | 2013-07-25 |
| ES2621413T3 (es) | 2017-07-04 |
| US10067120B2 (en) | 2018-09-04 |
| WO2012113802A1 (en) | 2012-08-30 |
| HUE032187T2 (en) | 2017-09-28 |
| NZ613022A (en) | 2015-11-27 |
| CA2824497A1 (en) | 2012-08-30 |
| JP6295081B2 (ja) | 2018-03-14 |
| CN103392130A (zh) | 2013-11-13 |
| US20140005237A1 (en) | 2014-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201306086B (en) | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | |
| GB201104096D0 (en) | Production of graphene | |
| ZA201403995B (en) | Stereoselective total synthesis of noribogaine | |
| IL233081A0 (en) | History of Betulin | |
| GB201002606D0 (en) | Production of fuels | |
| ZA201306520B (en) | Use of phospho-akt as a biomarker of drug response | |
| PT2666014T (pt) | Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos | |
| SG2014002240A (en) | Production of paraxylene | |
| EP2776586A4 (en) | BIOMARKERS OF REACTION ON PROTEASOMAL INHIBITORS | |
| EP2666016A1 (en) | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles | |
| GB201004096D0 (en) | Production of polyhydroalkanoates | |
| PT2666015T (pt) | Utilização de estatmina como um biomarcador da resposta farmacológica a furazanobenzimidazolos | |
| ZA201400248B (en) | Synthesis of cleistainthin a and derivatives thereof | |
| SG2014011639A (en) | Measuring form changes of a substrate | |
| GB2488866B (en) | Use of GPS to detect repetitive motion | |
| EP2680843A4 (en) | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS | |
| PL2465868T3 (pl) | Ulepszenie produkcji lipidów | |
| EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| EP2791349A4 (en) | SYNTHESIS OF N-ACETYL-D-NEURAMIC ACID | |
| ZA201207838B (en) | Use of zirconium or of a zirconium-comprising mixture | |
| GB201106098D0 (en) | Production of fuels | |
| TWM433471U (en) | Assembly structure of gear | |
| GB201110310D0 (en) | Paperless point of sale | |
| GB201103801D0 (en) | Movement of aircraft |